Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 11,500.00
Ask: 12,270.00
Change: 0.00 (0.00%)
Spread: 770.00 (6.696%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 1-Germany warns vaccinations alone will not contain COVID-19 third wave

Fri, 19th Mar 2021 12:41

* Spahn says doctors will now be more informed of risks

* Merkel to discuss speeding up rollout with state leaders

* Spahn says would favour supply deal for Russia's Sputnik V
(Adds details)

BERLIN, March 19 (Reuters) - Germany's health minister
warned on Friday there was not enough vaccine in Europe to
contain the COVID-19 third wave, as the country sought to get
its rollout back on track following a three-day pause in using
the AstraZeneca shot.

Case numbers have been rising in Germany, driven by an
easing of restrictions in recent weeks just as a more
transmissible variant of the virus has spread, underlining the
need to accelerate vaccinations to protect the vulnerable.

Health Minister Jens Spahn defended the suspension, which
was lifted on Thursday after European Union regulators said the
benefits outweighed the risk, as providing
transparency.

"We can reintroduce AstraZeneca but prudently with informed
doctors and appropriately educated citizens," he said in a
weekly news conference.

But he warned that vaccinations alone would not be able to
contain the third wave as there are not enough doses, and said
restrictions that were lifted may have to be reimposed to
contain the spread of the virus.

"The rising case numbers may mean that we cannot take
further opening steps in the weeks to come. On the contrary, we
may even have to take steps backwards," Spahn said.

State leaders are also due to discuss with Chancellor Angela
Merkel later on Friday ways to speed up the vaccination
campaign, among other by allowing family doctors to start
administering doses at their surgeries.

The suspension was the latest hurdle in Germany's
vaccination campaign, which has been plagued by delivery delays
and news reports of side-effects. As of Friday, just 8.5% of the
population had received a first shot, far behind other countries
like the United States and Britain.

German state leaders said they were ready to quickly catch
up on lost time. In Berlin, anyone who was due to receive an
AstraZeneca shot earlier in the week can turn up at vaccination
centres this weekend without an appointment.

YOUNGER WOMEN

Meanwhile, the premier of the southwestern German state of
Baden-Wuerttemberg, Winfried Kretschmann, 72, is due to receive
an AstraZeneca vaccination on Friday, in a move to shore up
confidence.

But Bodo Ramelow, the premier of Thuringia in eastern
Germany, said he would not advise his wife, who needs to use
blood thinners due to a risk of thrombosis, to get the
AstraZeneca shot although he would do so himself.

Karl Lauterbach, the main health expert of the SPD, Merkel's
junior coalition partner, said it was important to not create
the impression that the AstraZeneca vaccine was not suitable for
younger women.

In Germany, eight people were diagnosed with cerebral venous
sinus thrombosis (CVST) within about two weeks of being
vaccinated. They were among the 1.6 million recipients of the
shot as of Wednesday, with CVST cases higher among women.

Lauterbach said the higher incidence could be due to the
fact that younger women work in the health sector or in
kindergartens, groups that have received the AstraZeneca vaccine
in higher numbers.

Spahn said he hoped vaccinations could take place in
doctors' practices from April 19 at the latest, but warned that
supply would remain restricted.

Germany expects to receive 15 million doses of the
AstraZeneca vaccine in the second quarter, a few million fewer
than initially expected, he said.

Spahn also spoke out in favour of signing a supply deal for
the Russian Sputnik V vaccine for COVID-19, but said there
needed to be greater clarity on the quantities available.

(Reporting by Caroline Copley; Editing by Maria Sheahan and
Paul Simao)

More News
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more
25 Apr 2024 09:18

TOP NEWS: AstraZeneca upbeat as cancer drugs underpin sales growth

(Alliance News) - AstraZeneca PLC on Thursday hailed the potential of its drugs pipeline as it delivered impressive growth in sales and profit in the first quarter.

Read more
25 Apr 2024 09:12

LONDON MARKET OPEN: Anglo American jumps on takeover bid from BHP

(Alliance News) - Stock prices in London opened mixed on Thursday, as investors cautiously eye data on the health of the US economy.

Read more
25 Apr 2024 08:38

AstraZeneca blows past analysts' estimates for Q1

(Sharecast News) - AstraZeneca posted better-than-expected revenues and profit for the first quarter of 2024 with both the company and analysts highlighting its drug pipeline.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.